We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

More Accurate Prediction on Prognosis in Multiple Myeloma (Bone Marrow Cancer)

More Accurate Prediction on Prognosis in Multiple Myeloma (Bone Marrow Cancer)

More Accurate Prediction on Prognosis in Multiple Myeloma (Bone Marrow Cancer)

More Accurate Prediction on Prognosis in Multiple Myeloma (Bone Marrow Cancer)

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "More Accurate Prediction on Prognosis in Multiple Myeloma (Bone Marrow Cancer)"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SkylineDx, an innovative biotechnology company specialising in the development and commercialization of genetic tests, is today launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods. 

The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the disease. These measurements are repeated across different studies, always with the same robustness and predictable outcome, thereby creating a test that is more reliable than traditional methods. Based on gene activity, clinicians can then use the test to predict for their patients how the disease will progress. 

Unfortunately, between twenty and twenty-five percent of patients are informed that their prognosis is poorer. The overall survival of these patients is four times lower, on average, and these patients can expect the disease to return more quickly after treatment than patients with a better prognosis. Several guidelines for the treatment of multiple myeloma, like mSMART guidelines, recommend that patients be treated in accordance with their prognosis. 

Patients, patient advocacy organisations, internists and clinical geneticists have all expressed a strong interest in the new test. At a major European conference on blood and bone marrow cancers held in Vienna this June, it was revealed that approximately 80% of patients wanted to be informed about disease progress. 

‘"The key to a successful doctor-patient relationship is good communication – it isn’t rocket science. Ask and involve them, be honest and listen very carefully to what they have to say", says Mr Eric Low, chief executive officer of Myeloma UK, a patient advocacy group.

The new test is also supported by Prof. Dr. Sonneveld of Erasmus Medical Center in Rotterdam, who recently received the Robert A. Kyle Lifetime Achievement Award for his work on multiple myeloma:

"We want to be able to predict disease progress based on the genetic properties of the malignant cell. While the current methods accommodate this need to some extent, it makes more sense to mark all genes involved in the incidence of multiple myeloma at once. Based on the profile generated, we can then divide patients based on their better or poorer prognosis."